![Vincent Mutel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Vincent Mutel
Chief Executive Officer at Inflamalps SA
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Scherz | M | - |
Metys Pharmaceuticals AG
![]() Metys Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Part of Novaremed AG, Metys Pharmaceuticals AG is a pharmaceutical company based in Basel, Switzerland. The Swiss company specializes in developing dimiracetam for the prevention of chemotherapy-induced neuropathic pain. The company was founded by Michael Scherz, who has been the CEO since incorporation. Metys Pharmaceuticals was acquired by Novaremed AG on September 07, 2021. | 11 years |
Philippe Meuwly | M | - |
Inflamalps SA
![]() Inflamalps SA Pharmaceuticals: MajorHealth Technology Inflamalps SA operates as a biopharmaceutical company. The firm focuses on developing topical treatments for inflammation-mediated diseases in ophthalmology and dermatology. The company was founded by Charles Woler, Vincent Mutel and Philippe Meuwly in August 2012 and is headquartered in Monthey, Switzerlands. | 12 years |
Andrew Oakley | M | 62 |
Metys Pharmaceuticals AG
![]() Metys Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Part of Novaremed AG, Metys Pharmaceuticals AG is a pharmaceutical company based in Basel, Switzerland. The Swiss company specializes in developing dimiracetam for the prevention of chemotherapy-induced neuropathic pain. The company was founded by Michael Scherz, who has been the CEO since incorporation. Metys Pharmaceuticals was acquired by Novaremed AG on September 07, 2021. | - |
Wolfgang Söhngen | M | - |
Metys Pharmaceuticals AG
![]() Metys Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Part of Novaremed AG, Metys Pharmaceuticals AG is a pharmaceutical company based in Basel, Switzerland. The Swiss company specializes in developing dimiracetam for the prevention of chemotherapy-induced neuropathic pain. The company was founded by Michael Scherz, who has been the CEO since incorporation. Metys Pharmaceuticals was acquired by Novaremed AG on September 07, 2021. | - |
Mark Sumeray | M | 58 |
Metys Pharmaceuticals AG
![]() Metys Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Part of Novaremed AG, Metys Pharmaceuticals AG is a pharmaceutical company based in Basel, Switzerland. The Swiss company specializes in developing dimiracetam for the prevention of chemotherapy-induced neuropathic pain. The company was founded by Michael Scherz, who has been the CEO since incorporation. Metys Pharmaceuticals was acquired by Novaremed AG on September 07, 2021. | - |
Levon Khachaturyan | M | - |
Inflamalps SA
![]() Inflamalps SA Pharmaceuticals: MajorHealth Technology Inflamalps SA operates as a biopharmaceutical company. The firm focuses on developing topical treatments for inflammation-mediated diseases in ophthalmology and dermatology. The company was founded by Charles Woler, Vincent Mutel and Philippe Meuwly in August 2012 and is headquartered in Monthey, Switzerlands. | - |
Oleg Sharonov | M | - |
Inflamalps SA
![]() Inflamalps SA Pharmaceuticals: MajorHealth Technology Inflamalps SA operates as a biopharmaceutical company. The firm focuses on developing topical treatments for inflammation-mediated diseases in ophthalmology and dermatology. The company was founded by Charles Woler, Vincent Mutel and Philippe Meuwly in August 2012 and is headquartered in Monthey, Switzerlands. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Charles Woler | M | 74 |
Inflamalps SA
![]() Inflamalps SA Pharmaceuticals: MajorHealth Technology Inflamalps SA operates as a biopharmaceutical company. The firm focuses on developing topical treatments for inflammation-mediated diseases in ophthalmology and dermatology. The company was founded by Charles Woler, Vincent Mutel and Philippe Meuwly in August 2012 and is headquartered in Monthey, Switzerlands. | - |
Olivier Jean Bohuon | M | 65 |
University of Paris Jussieu
| 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
Switzerland | 8 | 88.89% |
France | 1 | 11.11% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Vincent Mutel
- Personal Network